npj Breast Cancer

Article	Citations
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer	672
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer	318
Biological correlates associated with high-risk breast cancer patients identified using a computational method	190
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer	125
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination	123
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers	113
A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence	103
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab	97
CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer	90
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer	88
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer	87
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer	85
International survey on invasive lobular breast cancer identifies priority research questions	73
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	68
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021	66
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	65
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients	64
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)	63
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer	62
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice	58
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial	57
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events	55
Circulating tumor DNA validity and potential uses in metastatic breast cancer	50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer	49
Host-derived interleukin-1α drives tumor immunosuppression by reprogramming tumor-associated myeloid cells	47

Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions	47
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer	47
Breastfeeding attributable fraction of triple negative breast cancer in the US	45
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays	45
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines	44
Survival outcomes after omission of surgery for ductal carcinoma in situ	42
Clinical outcome and proportion of hereditary cancer genes gPV in TNBC: the HEaRTBeat study	42
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)	42
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer	40
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer	40
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer	38
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center	37
Temporal evolution of breast cancer brain metastases treatments and outcomes	37
Understanding metastasis mixed-treatment responses through genomic analyses	37
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer	36
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature	35
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification	35
Kataegis in clinical and molecular subgroups of primary breast cancer	35
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer	35
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling	34
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 2016	33
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment	33
Large language model (ChatGPT) as a support tool for breast tumor board	32
Breast cancers arising in high mammographic density tissue harbor tumor-promoting immune profiles	31
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	31
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance	30
Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6	30
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries	30
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment	29
Functional assays for BRCA1 and BRCA2 variant analysis: new tools and their applications	28
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer	28
Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States	28
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin	28
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer	27
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program	26
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial	26
Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer	26
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies	25
Cook and Move for Your Life, an eHealth intervention for women with breast cancer	25
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer	25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer	25
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry	24
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study	23
A systematic review of determinants of breast cancer risk among women with benign breast disease	23
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer	23
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab	23
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy	23
Prognostic value of structural variants in early breast cancer patients	22
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	22
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer	22

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis	22
Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer	22
SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning	22
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies	22
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study	21
Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history	21
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer	21
Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation	21
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer	21
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers	21
Author Correction: Advancing equitable access to innovation in breast cancer	20
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation	20
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy	20
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer	20
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape	19
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women	19
Phase II trial of anlotinib-chemotherapy combination in pretreated HER2-negative metastatic breast cancer: therapeutic efficacy and proteomic biomarker profiling	19
Evaluating mammographic density′s contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors	19
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer	18
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry	18
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence	18
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer	18
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer	18
Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer	18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases	18
Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer	17
Racial discrimination among women seeking breast cancer care	17
Plasma C-peptide mammographic features and risk of breast cancer	17
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence	17
Author Correction: Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer	17
Proteogenomic characterization of invasive breast tumors in young women	17
The association between local therapies and survival among patients with metastatic inflammatory breast cancer	17
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention	17
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts	16
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumour	16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer	16
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy	16
Advancing equitable access to innovation in breast cancer	16
Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer	16
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases	16
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer	16
Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer	16
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer	16
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study	16
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer	15
Disparities in breast cancer incidence and survival by age, race, and molecular subtype in US women	15
Genomic landscape of breast cancer in elderly patients	15
Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors	15
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial	15
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer	15
Post-diagnosis weight trajectories and mortality among women with breast cancer	15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics	15
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib	15
Artificial intelligence in breast pathology – dawn of a new era	15
Genomic landscapes of breast cancer in African populations: a systematic review	14
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study	14
Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer	14
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer	14
Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer	14
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer	14
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer	14
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery	14
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer	14
Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance	14
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer	13
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study	13
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials	13
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients	13
Artificial intelligence assisted multi-model pathological diagnosis of breast cancer based on multispectral autofluorescence images	13
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR	12
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer	12
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer	12
An emerging generation of endocrine therapies in breast cancer: a clinical perspective	12
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer	12
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease	12
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy	12
Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort	12
Trimester of diagnosis affects tumor characteristics and survival in breast cancer during pregnancy: first results from the STURGATE collaboration	11
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management	11
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications	11

Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden	11
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation	11
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer	11
Computerized cognitive training improves cognitive function in primary breast cancer survivors	11
Bridging the gap: ctDNA, genomics, and equity in breast cancer care	11
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients	10
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning	10
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer	10
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade	10
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer	10
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study	10
Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision	10
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes	10
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs	10
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers	10
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer	10
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools	10
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ	10
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function	10
The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer	9
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer	9
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis	9
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial	9
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy	9
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer	9
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer	9
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study	9
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment	8
Cancer cell-monocyte co-culture spheroids recapitulate pro-tumorigenic, immunosuppressive, and drug-resistant microenvironments in brain metastatic breast cancer	8
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes	8
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab	8
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer	8
Effects of acute exercise on inflammatory and metabolic biomarkers in women: a randomized controlled trial	8
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death	8
Allostatic load as a predictor of postoperative complications in patients with breast cancer	8
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing	8
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)	8
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes	8
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research	8
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial	8
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer	8
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer	8
Author Correction: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer	8
Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer	8
Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset	8
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis	8
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer	8
HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis	8
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis	8
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling	8
Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer	7
Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel	7
Author Correction: Development and characterisation of a novel 3D in vitro model of obesity-associated breast cancer as a tool for drug testing	7
Modeling tumor relapse using proliferation tracing and ablation transgenic mouse	7
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients	7
CBD-oil as a potential solution in case of severe tamoxifen-related side effects	7
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer	7
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis	7
Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology	7
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer	7
Immunotherapy in breast cancer: an overview of current strategies and perspectives	7
Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer	7
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study	7
Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives	7
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy	7
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy	7
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis	6
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen	6
Tractable mouse TNBC models capture the heterogeneous tumor immune microenvironment and adaptation to PD-L1 blockade	6
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets	6
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies	6
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC	6
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer	6
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer	6
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models	6
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer	6
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy	6
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study	6
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer	6
Characterization of body composition dynamics throughout treatment in patients with early-stage breast cancer	6
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer	5
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis	5
Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer	5
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer	5
NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer	5
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial	5
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)	5
Triple negative breast cancer: Pitfalls and progress	5
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype	5
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer	5
Reversion of breast epithelial polarity alterations caused by obesity	5
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification	5
Immune landscape of breast tumors with low and intermediate estrogen receptor expression	5
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)	5
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets	5